Portal › Forums › Lung/Thoracic Cancer › General Lung/Thoracic Cancer › ASCO 2013 Video: Can we target KRAS effectively in advanced NSCLC?
This topic contains 0 replies, has 1 voice, and was last updated by JimC Forum Moderator 4 years, 10 months ago.
In today’s ASCO 2013 video, Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.
You can view the video here: http://cancergrace.org/lung/2013/07/03/mek-inhibitor-update-asco-2013/
We welcome your questions and comments here.
Jul 2008 Wife Liz (51/never smoker) Dx Stage IV NSCLC EGFR exon 19
4 cycles Carbo/alimta, 65% shrinkage
Mar 2010 progression, added Alimta, stable
Sep 2010 multiple brain mets, WBR
Oct 2010 large pericardial effusion, tamponade
Jan 2011 progression, start abraxane
Jun 2011-New liver, brain mets, add Tarceva
Oct 2011-Dx Leptomeningeal carcinomatosis; pulsed Tarceva
At rest Nov 4 2011
Since then: http://cancergrace.org/blog/jim-and-lisa
You must be logged in to reply to this topic.
Subscribe toGRACE Notes (Free Newsletter)
Mission | Disclaimer